PROK vs REPL

ProKidney Corp. vs Replimune Group, Inc. — Valuation Comparison 2026

PROK

Biological Products, (No Diagnostic Substances)
ProKidney Corp.
Quality
4.3
out of 10
Value Trap
6
SAFE
Price
$1.83
Last close
Models
9/13
Active
VS

REPL

Biological Products, (No Diagnostic Substances)
Replimune Group, Inc.
Quality
4.4
out of 10
Value Trap
18
SAFE
Price
$8.69
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType PROK Fair ValuePROK Upside REPL Fair ValueREPL Upside
Bayesian DCF Intrinsic $0.62 -65.9% $1.76 -79.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.49 -75.1% $2.22 -74.5%
Dynamic NAV Asset-Based $0.78 -57.6% $3.58 -58.8%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PROK vs REPL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PROK vs REPL — Which Stock Is More Undervalued?

REPL scores higher with a 4.4/10 quality rating vs PROK's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ProKidney Corp. (PROK) and Replimune Group, Inc. (REPL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PROK currently trades at $1.83 with a QOC of 4.3/10, while REPL trades at $8.69 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).